Proteins of the WNT signaling pathway and uses thereof in the diagnostic and treatment of hypopigmentation disorders
AssigneesInserm (Institut National De La Sante Et De La Recherche Medicale), Université CôTe D'Azur, Chu De Nice
InventorsThierry Passeron, Florence Joly
Life of this patent
Estimating the term…
Abstract
The present invention relates to the identification of proteins of the WNT signaling pathway as therapeutic targets of pigmentation disorder and as biomarkers of pigmentation status. The invention in particular relates to products and methods for treating a hypopigmentation disorder. The invention also relates to products and methods for detecting, diagnosing, staging or monitoring the course of hypopigmentation disorder and is particularly suited for human subjects.
Claims6
A method for treating Vitiligo disorder and/or repigmenting a Vitiligo lesion in a subject by inducing differentiation of melanocyte stem cells, comprising administering to the subject in need thereof an activator of at least one protein of the WNT signalling pathway selected from MITF (Microphthalmia-associated transcription factor) and PAX3 (transcription factor 3 of the paired box (PAX) family) in an amount sufficient to induce differentiation of melanocyte stem cells, wherein the activator is SKL2001.
Dependencies are inferred from the claim text.